Abstract
Control of hypertension is well established for the primary prevention of stroke. Prior studies, on the other hand, conflict over whether hypertension remains a risk factor for recurrent stroke and if blood pressure reduction is associated with better outcomes in this subset of patients. We review current evidence regarding the role of BP lowering for primary and secondary prevention of stroke. Current evidence amassed from both primary and secondary prevention trials demonstrate that BP reduction is a crucial common element in overall reduction of stroke risk.
Keywords: Stroke, hypertension, blood pressure
Current Vascular Pharmacology
Title: Blood Pressure Reduction in the Primary and Secondary Prevention of Stroke
Volume: 4 Issue: 2
Author(s): Seth I. Sokol, John R. Kapoor and JoAnne M. Foody
Affiliation:
Keywords: Stroke, hypertension, blood pressure
Abstract: Control of hypertension is well established for the primary prevention of stroke. Prior studies, on the other hand, conflict over whether hypertension remains a risk factor for recurrent stroke and if blood pressure reduction is associated with better outcomes in this subset of patients. We review current evidence regarding the role of BP lowering for primary and secondary prevention of stroke. Current evidence amassed from both primary and secondary prevention trials demonstrate that BP reduction is a crucial common element in overall reduction of stroke risk.
Export Options
About this article
Cite this article as:
Sokol I. Seth, Kapoor R. John and Foody M. JoAnne, Blood Pressure Reduction in the Primary and Secondary Prevention of Stroke, Current Vascular Pharmacology 2006; 4 (2) . https://dx.doi.org/10.2174/157016106776359862
DOI https://dx.doi.org/10.2174/157016106776359862 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Autonomic Responses After Isometric Training at Different Intensities on Obese People
Current Hypertension Reviews The Pharmacologic Approach to the Prevention of Preeclampsia: From Antiplatelet, Antithrombosis and Antioxidant Therapy to Anticonvulsants
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Chemotherapeutic Options for Colorectal Cancer Patients with Cardiovascular Diseases.
Reviews on Recent Clinical Trials Increased Pulmonary Heme Oxygenase-1 and δ-Aminolevulinate Synthase Expression in Monocrotaline-Induced Pulmonary Hypertension
Current Neurovascular Research The Effects of Incretins on Energy Homeostasis: Physiology and Implications for the Treatment of Type 2 Diabetes Mellitus and Obesity
Current Vascular Pharmacology Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Genetics of Polygenic Hypertension from Animal Models to Humans
Current Hypertension Reviews Turnover Studies on Cardiac Natriuretic Peptides: Methodological,Pathophysiological and Therapeutical Considerations.
Current Drug Metabolism Weight Loss in Obesity and Metabolic Syndrome
Current Hypertension Reviews Pharmacogenomics of Essential Hypertension: Are We Going the Right Way?
Cardiovascular & Hematological Agents in Medicinal Chemistry Vitamin D: Evolutionary, Physiological and Health Perspectives
Current Drug Targets Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Novel Anticoagulants vs Warfarin for Stroke Prevention in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Progress and Issues of the Genome-Wide Association Study for Hypertension
Current Medicinal Chemistry Opioid Growth Factor and its Derivatives as Potential Non-toxic Multifunctional Anticancer and Analgesic Compounds
Current Medicinal Chemistry Hemoglobin Encapsulated Poly(Ethylene Glycol) Surface Conjugated Vesicles Attenuate Vasoactivity of Cell-Free Hemoglobin
Current Drug Discovery Technologies Recent Studies of Antioxidant Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders
Current Pharmaceutical Design Osteoblastic Responses to LPS, Glucose-oxidised LDL and Minocycline: Therapeutic Targets for Periodontal and Cardiometabolic Diseases
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Glaucoma Eye Drops Adverse Skin Reactions
Recent Patents on Inflammation & Allergy Drug Discovery